Advancements in the Treatment of Multiple Myeloma.

Multiple myeloma (MM) is the second most common hematological malignancy globally. Despite its reputation as an aggressive and fatal disease, recent advancements in treatment have significantly improved patient outcomes. Over the past decade, innovative therapies with fewer side effects have emerged, including proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib), monoclonal antibodies (e.g., daratumumab, isatuximab, elotuzumab), immunomodulators (e.g., thalidomide, lenalidomide, pomalidomide), and corticosteroids (e.g., dexamethasone). Additionally, combination regimens utilizing these agents have demonstrated improved efficacy by targeting multiple pathways simultaneously. These therapies are more precise in their ability to attack myeloma cells, leading to enhanced patient quality of life, prolonged remission, and delayed disease progression. This article explores the evolution of MM therapies, highlighting the potential for a cure through ongoing breakthroughs in drug development and combination treatments. The analysis underscores the optimism surrounding the future of MM treatment and the need for continued research to make MM a manageable and potentially curable disease.